Pharming Group Promoted to Euronext AMX Index from September 2025

Pharming Group N.V. has been promoted from the Euronext AScX Small Cap index to the AMX MidCap index due to its strong growth momentum, which is expected to boost its visibility and attractiveness to investors. Glenmark Pharmaceuticals received a significant $700 million upfront payment from AbbVie for an exclusive global licensing deal on its investigational asset ISB 2001, enhancing Glenmark's financial position and R&D capabilities despite a recent drop in net profit. Morepen Laboratories Limited saw its shares rise following a joint venture agreement with UAE-based Bimedical FZE to establish a medical device manufacturing company in India, aligning with its strategic expansion despite recent declines in revenue and profit. Meanwhile, MediNet Group Limited's shares surged by 52% in a month despite declining revenue, reflecting a low price-to-sales ratio that suggests cautious investor sentiment due to its underperformance relative to the healthcare industry. Pharming Group’s shares also jumped 26% recently, supported by strong revenue growth over the past three years, but its relatively low price-to-sales ratio indicates market expectations of modest future growth. These developments highlight varied trajectories within the pharmaceutical sector, with companies leveraging partnerships and market reclassifications to drive growth amidst differing financial performances.